IR415

Research use only, not for human use.

IR415 is a novel small molecule inhibitor of HBV virus replication that blocks hepatitis B virus X protein (HBx, Kd=2 nM) mediated RNAi suppression.

IR415 is a novel small molecule inhibitor of HBV virus replication that blocks hepatitis B virus X protein (HBx, Kd=2 nM) mediated RNAi suppression, reverses the inhibitory effect of HBx protein on activity of the Dicer endoribonuclease; exhibits a marked depletion of HBV core protein synthesis and down-regulation of pre-genomic HBV RNA in HBV-infected HepG2 cells, selectively targets HBx in a concentration-dependent manner.

Hepatitis B virus X protein (HBx) as a suppressor of host defenses consisting of RNAi-based silencing of viral genes.IR415 (50-200 μM) has a dose-dependent inhibitory effect on HBx, with a minimal effective concentration of 50 μM in HepG2/GFP-shRNA line transfected with HBx.

——

IR 415 | IR-415

Microbiology/Virology

HBV

HBV

——

——

452967-14-5

296.34

C13H14F2N4S

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (421.81 mM)

——

N-(2,4-difluorophenyl)-N'-[3-(1H-imidazol-1-yl) propyl] thiourea

(-20℃)

With Ice Pack

≥ 2 years